Alnylam appoints Pushkal Garg as chief research and development officer

CAMBRIDGE, Mass. - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has appointed Pushkal Garg, M.D., as Executive Vice President, Chief Research and Development Officer to lead a newly integrated R&D organization, according to a company press release.

The RNA interference (RNAi) therapeutics company is restructuring its R&D operations following the launch of AMVUTTRA for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The company states the combined organization aims to accelerate pipeline progress through earlier collaboration and faster decision-making.

Dr. Garg joined Alnylam in 2014 to build and lead the company’s Development group. His previous experience includes leadership roles at Bristol-Myers Squibb and Millennium Pharmaceuticals. He holds a B.A. in Biochemistry from UC Berkeley and an M.D. from UC San Francisco.

The company has set a goal of delivering RNAi therapeutics to all major tissues in the body by 2030. RNAi is a natural cellular process of gene silencing that was recognized with the 2006 Nobel Prize for Physiology or Medicine. According to InvestingPro analysis, which offers 12 additional valuable insights about Alnylam’s performance and prospects, analysts expect the company to achieve profitability this year, supporting its ambitious expansion plans.

Alnylam, headquartered in Cambridge, Massachusetts, focuses on developing treatments for both rare and common diseases using RNAi technology, which works by silencing messenger RNA that encodes for disease-causing proteins.

The company is currently executing what it calls its "Alnylam P5x25" strategy, which aims to deliver transformative medicines while achieving financial performance targets.

In other recent news, Alnylam Pharmaceuticals has reported significant developments concerning its RNAi therapeutic, Amvuttra. The European Commission has approved Amvuttra for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM), marking the first such approval for an RNAi therapy in this condition. This follows the HELIOS-B Phase 3 study results, which showed notable reductions in mortality and improvements in patient quality of life. RBC Capital and H.C. Wainwright have maintained their positive outlooks on Alnylam, with price targets of $330 and $500, respectively, citing strong initial results from the Amvuttra launch and the company’s path to profitability. RBC Capital’s survey of U.S. cardiologists indicates Amvuttra’s rapid adoption, with 81% of doctors having prescribed the treatment. Meanwhile, Alnylam’s broader pipeline is advancing, with upcoming trials for other therapeutics. Analysts at H.C. Wainwright express confidence in Alnylam’s sustained revenue growth, driven by innovation and geographic expansion. Alnylam’s executives highlight the strong formulary access and minimal payer resistance, contributing to the company’s optimistic market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.